Call for Abstracts

Abstract submission for IASLC WCLC 2019 is NOW OPEN!

Submit Your Abstract(s) Here

Submission Categories

The Core Program and Regional Organizing Committee for the IASLC 20th World Conference on Lung Cancer are inviting the submission of scientific abstracts. Authors are asked to submit abstracts under one of the following categories:

  • Advanced NSCLC
  • Advocacy
  • Biology
  • Immunooncology
  • Interventional Diagnostics/Pulmonology
  • Mesothelioma
  • Nursing and Allied Professionals
  • Oligometastatic NSCLC
  • Pathology
  • Prevention and Tobacco Control
  • Screening and Early Detection
  • Small Cell Lung Cancer/NET
  • Staging
  • Targeted Therapy
  • Thymoma/Other Thoracic Malignancies
  • Treatment in the Real World - Support, Survivorship, Systems Research
  • Treatment of Early Stage/Localized Disease
  • Treatment of Locoregional Disease - NSCLC


Clinical Trial in Progress

Clinical Trial in Progress

  • The Conference will also accept submissions of abstracts on Clinical Trial in Progress and encore Trial in Progress abstracts
  • Trial in Progress abstracts are accepted
  • Trials in Progress which has not started enrollment by the abstract submission deadline must specify the timelines in the abstract
  • They should be submitted in the submission category that best fits the topic of the abstract
Submission Guidelines


  • Abstracts must not exceed 400 words in length (not including title and authors)
  • Tables may be included and each will count as 100 words
  • A maximum of 2 images may be included; each will count as 100 words
  • Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
  • Abstracts must be structured with the following:
    • Background
    • Methods
    • Results
    • Conclusion
  • Abstracts will be accepted in English only
  • An international panel of reviewers will review all abstracts anonymously
  • There is no fee for submitting an abstract
  • There is no limit to the number of abstracts you may submit (however an individual may not be offered more than 2 oral presentations)
  • All Abstracts accepted by the Scientific Committee will be published in the Journal of Thoracic Oncology (JTO) and the Conference website prior to the meeting and it is mandatory to agree to this at the time of submission

Step 1. Title & Topic

  • The abstract title must not exceed 125 characters in length; this includes spaces.

Step 2. Authors

  • The presenting author of an accepted abstract must be registered by July 5, 2019
  • There is no limit to the number of co-authors per abstract
  • Financial Disclosure information needs to be completed for EACH co-author at the time of submission through the online abstract submission form; however, information can be provided by the submitting author
  • The submitter can view the status of co-author disclosures by clicking on ‘Authors’ sections of the abstract. Those with incomplete disclosures are denoted in red
  • If you would like an assistant or other person to receive notifications regarding the status of an abstract, please enter their email address on the text field provided below the list of co-authors
  • Please note your preferred presentation format. If you would not be comfortable giving an oral presentation, please select Poster Only. NOTE: Selecting Poster/Oral does not guarantee you will be assigned an oral abstract presentation upon acceptance; the final presentation type is determined by the International Scientific Abstract Review Committee

Step 3. Disclosure

*ACCME Definition of a Commercial Interest: A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
Based on the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, the IASLC adheres to the following:

A) All individuals in a position to control the educational content of a CME activity MUST disclose all financial relationships of themselves and/or their spouse/partner with an ACCME-defined commercial interest* prior to the CME activity.

B) Should it be determined that a conflict of interest exists, the conflict MUST be resolved prior to the CME activity.

C) An individual who refuses to disclose financial relationships will be disqualified from being an activity director, planning committee member, speaker/moderator, author, or reviewer of CME and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. 

D) Employees of ACCME defined commercial interest may not serve as faculty or planners or another roles where they are in a position to control the content of accredit CME.

Disclosure of Relevant Financial Relationships:

  • The author must disclose all entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with which the author/the author’s spouse/partner have, or have had, a relevant financial relationship within the past 12 months. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
  • If the author has a relevant financial relationship, please provide the nature of relevant financial relationship as well as the name of company(s).

Disclosure  Affirmations:

  • I have disclosed to the IASLC all relevant financial relationships and I understand that the IASLC will disclose this information to participants in advance of the activity. In addition, I understand that participants will be asked to evaluate whether my contribution to a CME activity is educational, and not promotional, in nature.
  • The content and/or presentation of the information with which I am involved will promote quality or improvements in healthcare and will not promote a specific proprietary business interest of a commercial interest. Content for this activity, including any presentation of therapeutic options, will be well-balanced, evidence-based and unbiased.
  • If I am providing recommendations involving clinical medicine, they will be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support of a patient care recommendation will conform to the generally accepted standard of experimental design, data collection and analysis.
  • I have not and will not accept any honoraria, additional payments or reimbursements from a commercial interest for my participation in this activity.
  • I understand that my presentation will be monitored to ensure that it is educational and not commercial in nature.
  • If I am discussing specific health care products or services, I will use generic names to the extent possible. If I need to use trade names, I will use trade names from several companies when available, and not just trade names from any single company.
  • I agree to disclose to the audience whether a pharmaceutical or medical device introduced during this educational activity is classified by the FDA as “investigational” or “off-label” with respect to the intended use.
  • If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
  • I agree that if the IASLC is considering or involved with any subject in which I have a conflict of interest, I will not participate in any discussion or action on that subject unless officially requested to do so by the IASLC.
  • I have read and understand the IASLC’s Conflict of Interest Disclosure and Resolution Policy and agree to comply with the policy.
  • I agree that if a potential conflict of interest arises which has not been reported previously, I will immediately notify the IASLC in writing.

Step 4. Abstract Text

  • Do not include Title or Author data in the body of your abstract (There are specific places for Title and Author)
  • Abstracts may be entered directly into the site or copied and pasted
  • Research work should be original and innovative. Work can be presented prior to the IASLC 20th WCLC, but MUST include new information/data
  • Abstracts must not exceed 400 words in length (not including title and authors)
  • Tables may be included and each will count as 100 words
  • A maximum of 2 images may be included; each will count as 100 words
  • Tables, images and graphs must be uploaded in GIF, JPEG, JPG or PNG format at 300 dpi and 100% size. Any higher resolution is acceptable.
  • Abstracts must be structured with the following:
    • Background
    • Methods
    • Results
    • Conclusion

Step 5. Preview & Submit

  • Please proofread your submission prior to submitting
  • Once submitted, you will be able to make edits to the abstract. If you need to make changes after the submission deadline, please contact us at wclc2019-abstracts at

Please carefully review the affiliation of all your co-authors as this is how it will appear in the JTO and as well as the IASLC WCLC 2019 Scientific Program


Late-Breaking Abstract Submission
  • In order for an abstract to be considered for Late-Breaking Abstract status, the submitting author must submit a place holder (including author information and disclosure) abstract before the April 10, 2019 deadline (23:59 PST)
  • The results and conclusion can be omitted but the type of data that will be presented in Late-Breaking Abstract must be described as well as why Late-Breaking status is required
  • To apply for Late-Breaking Abstract privileges, you must send an email to wclc2019-abstracts at, indicating your abstract ID number and explaining why data is not yet available and when you expect it to become available on or before April 10, 2019 (23:59 PST).
  • The Core Program Committee will then review your abstract and application. If your application is approved you will be notified and instructed on how to submit your new data 
  • The Late-Breaking Abstract final data submission deadline is July 19, 2019
Important Deadlines

Important Deadlines

  • Abstract Submission Deadline: April 10, 2019 (23:59 PST); late breaking abstract placeholder must be submitted by April 10, 2019 (23:59)
  • Author Notification of Acceptance Sent: May 17, 2019
  • Travel Award Notifications Sent: June 7, 2019
  • Presenting Author Registration Deadline: July 5, 2019
  • Presenting Author and Abstract Title Changes Deadline: July 5, 2019
  • Late-Breaking Abstract Final Data Submission Deadline: July 19, 2019
  • Late-Breaking Abstract Notifications: July 22, 2019
  • Oral and Mini Oral Presentation Slide Submission Deadline: August 5, 2019
  • Full Abstracts Release Date: August 21, 2019 (5pm Eastern Time)
  • Poster Presentation Slide Submission Deadline: August 30, 2019
Frequently Asked Questions

When will the Peer Review and Late-Breaking abstract titles and abstract body be published online?

  • August 21, 2019 at 5pm Eastern Time. 

Does WCLC accept abstracts that have been submitted and presented to a previous Congress (ie, encore abstracts, trials in progress encore abstracts)?

  • Yes, we will accept encore abstracts. Please note this may affect the submitter’s rating. Encore submissions of trial in progress abstracts are accepted as long as the enrollment timelines are specified in the abstract

Are case reports/case series considered for presentations?

  • Yes, we do allow the submission of case reports.

What is the withdraw deadline for regular submissions and late breaking submissions?

  • Presenting author registration deadline is July 5, 2019. Any abstract presenters not registered by this date, their abstracts may be withdrawn from the program.

For late-breaking abstracts, does the congress only permit abstracts that report on Phase 3 [and higher] studies?

  • There are no guidelines/regulations as to which trials or studies can apply for late breaking privileges. We do not restrict late breaking privileges to ‘reports on Phase 3 (and higher) studies’.

Could I send my manuscript to publish to a journal in my country before WCLC?

  • If the abstract is published in a journal before WCLC, it may affect his rating. There are no rules that prevent submitters from having their abstract published in a journal before WCLC.

Is industry allowed to be in lead or senior author positions on the by-line for WCLC abstract submissions?

  • Yes, industry is allowed.

Does the restriction towards pharmaceutical/commercial authors apply to all abstracts submitted or is it just those accepted for oral and mini oral presentation?

  • Oral and Mini Oral presentations are prohibited from being presented by industry authors. The restriction does not apply for poster presentations since posters are not CME accredited.

Would it be possible to submit an abstract without results and conclusion?

  • You must submit a placeholder abstract by April 10, 2019 (23:59 PST). Please note abstracts submitted without results and conclusion may affect the rating of the abstract.

Is there a limit on the number of abstracts in which an author can be lead author?

  • There is no limit to the number of abstracts in which an author can be lead author. An individual may not be offered more than 2 oral presentations.

Is there any charge for the submission of abstracts, and if so how much is it?

  • No, there is no charge to submit an abstract to WCLC.

For inquiries, please contact wclc2019-abstracts at If your inquiry is regarding a particular draft or submission, please include the abstract ID in your email.